Evidence map›Paper›PMID 40267266›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Aβ

Neha Singh-Reilly, Jonathan Graff-Radford, Danni Li, Michelle M Mielke, Mary M Machulda, Christopher G Schwarz, Matthew L Senjem, Clifford R Jack, Val J Lowe, Keith A Josephs and 1 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Neha Singh-ReillyDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3614-9179
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2770-0691
Danni LiDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0608-2831
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University, Winston-Salem, NC, USA.ORCID 0000-0001-7177-1185
Mary M MachuldaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4834-5967
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1466-8357
Matthew L SenjemDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9308-9275
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7916-622X
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5612-1667
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2930-8634
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-6914-1563

Funding

Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
NIA NIH HHS R01 AG050603NIA NIH HHS R37 AG011378
6 · The paper itself

Abstract

BackgroundStudies suggest that plasma Alzheimer's disease (AD) biomarkers may aid in the overall diagnosis of AD, but their utility among patients with atypical clinical presentations of AD are unknown.ObjectiveThe main objective of this study was to determine the relationship between amyloid-β (Aβ) and tau plasma biomarkers and PET measures of both Aβ and tau in atypical AD. The secondary objective was to determine if plasma biomarkers could differentiate patients with different atypical AD phenotypes and whether they were related to measures of disease severity.MethodsWe assessed whether plasma p-tau 181 and Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide Fragmentstau ProteinsAgedAged, 80 and overBiomarkersBrainFemaleHumansMaleMiddle AgedPositron-Emission TomographyAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)amyloid beta-protein (40-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer's diseaseamyloid-βblood plasmapositron emission tomographytau protein

Identifiers

PMID40267266
PMCPMC12208405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.